Gilead Sciences Files SC 13D/A for Assembly Biosciences

Ticker: GILD · Form: SC 13D/A · Filed: 2024-06-20T00:00:00.000Z

Sentiment: neutral

Topics: ownership-change, sec-filing, biotech

Related Tickers: ASMB, GILD

TL;DR

Gilead just updated its stake in Assembly Bio. Watch this space.

AI Summary

On June 20, 2024, Gilead Sciences, Inc. filed an amendment to its Schedule 13D concerning Assembly Biosciences, Inc. This filing indicates a change in beneficial ownership for Gilead Sciences, Inc. regarding Assembly Biosciences, Inc. common stock.

Why It Matters

This filing signals a potential shift in control or significant investment by Gilead Sciences in Assembly Biosciences, which could impact Assembly's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate strategic moves by large companies, potentially leading to volatility for the target company.

Key Players & Entities

FAQ

What specific change in beneficial ownership is Gilead Sciences reporting for Assembly Biosciences?

The filing is an amendment to Schedule 13D, indicating a change in beneficial ownership, but the exact percentage or number of shares acquired/disposed of is not detailed in the provided header information.

When was this amendment filed with the SEC?

This amendment was filed on June 20, 2024.

What is the CUSIP number for Assembly Biosciences, Inc. common stock?

The CUSIP number for Assembly Biosciences, Inc. common stock is 0453961080.

What is the business address of Gilead Sciences, Inc. as listed in the filing?

Gilead Sciences, Inc.'s business address is 333 Lakeside Drive, Foster City, California 94404.

What was Assembly Biosciences, Inc. formerly known as?

Assembly Biosciences, Inc. was formerly known as Ventrus Biosciences Inc., with a date of name change on February 11, 2008.

From the Filing

0000904454-24-000393.txt : 20240620 0000904454-24-000393.hdr.sgml : 20240620 20240620203537 ACCESSION NUMBER: 0000904454-24-000393 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85836 FILM NUMBER: 241058166 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13D/A 1 s13da_061724-assemblybio.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 17, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 0453961080 Page 2 1 NAME OF REPORTING PERSONS Gilead Sciences, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1,268,972 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 1,268,972 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,268,972 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN

View on Read The Filing